Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311280444> ?p ?o ?g. }
- W4311280444 endingPage "615" @default.
- W4311280444 startingPage "598" @default.
- W4311280444 abstract "Abstract ROS1 tyrosine kinase inhibitors (TKI) have been approved (crizotinib and entrectinib) or explored (lorlatinib, taletrectinib, and repotrectinib) for the treatment of ROS1 fusion–positive cancers, although none of them simultaneously address the need for broad resistance coverage, avoidance of clinically dose-limiting TRK inhibition, and brain penetration. NVL-520 is a rationally designed macrocycle with >50-fold ROS1 selectivity over 98% of the kinome tested. It is active in vitro against diverse ROS1 fusions and resistance mutations and exhibits 10- to 1,000-fold improved potency for the ROS1 G2032R solvent-front mutation over crizotinib, entrectinib, lorlatinib, taletrectinib, and repotrectinib. In vivo, it induces tumor regression in G2032R-inclusive intracranial and patient-derived xenograft models. Importantly, NVL-520 has an ∼100-fold increased potency for ROS1 and ROS1 G2032R over TRK. As a clinical proof of concept, NVL-520 elicited objective tumor responses in three patients with TKI-refractory ROS1 fusion–positive lung cancers, including two with ROS1 G2032R and one with intracranial metastases, with no observed neurologic toxicities. Significance: The combined preclinical features of NVL-520 that include potent targeting of ROS1 and diverse ROS1 resistance mutations, high selectivity for ROS1 G2032R over TRK, and brain penetration mark the development of a distinct ROS1 TKI with the potential to surpass the limitations of earlier-generation TKIs for ROS1 fusion–positive patients. This article is highlighted in the In This Issue feature, p. 517" @default.
- W4311280444 created "2022-12-25" @default.
- W4311280444 creator A5000786006 @default.
- W4311280444 creator A5001144101 @default.
- W4311280444 creator A5006829324 @default.
- W4311280444 creator A5011828578 @default.
- W4311280444 creator A5013652949 @default.
- W4311280444 creator A5022400371 @default.
- W4311280444 creator A5023794502 @default.
- W4311280444 creator A5025489995 @default.
- W4311280444 creator A5025836672 @default.
- W4311280444 creator A5030929043 @default.
- W4311280444 creator A5033526813 @default.
- W4311280444 creator A5041971186 @default.
- W4311280444 creator A5044838791 @default.
- W4311280444 creator A5045185741 @default.
- W4311280444 creator A5051093087 @default.
- W4311280444 creator A5051177611 @default.
- W4311280444 creator A5063199354 @default.
- W4311280444 creator A5073804933 @default.
- W4311280444 creator A5074480973 @default.
- W4311280444 creator A5082517668 @default.
- W4311280444 creator A5084707465 @default.
- W4311280444 creator A5085217465 @default.
- W4311280444 creator A5087906702 @default.
- W4311280444 creator A5087923582 @default.
- W4311280444 date "2022-12-13" @default.
- W4311280444 modified "2023-10-16" @default.
- W4311280444 title "NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations" @default.
- W4311280444 cites W1969391810 @default.
- W4311280444 cites W2022319775 @default.
- W4311280444 cites W2024625433 @default.
- W4311280444 cites W2030586486 @default.
- W4311280444 cites W2034269086 @default.
- W4311280444 cites W2052546787 @default.
- W4311280444 cites W2053954823 @default.
- W4311280444 cites W2069826554 @default.
- W4311280444 cites W2127129900 @default.
- W4311280444 cites W2138362890 @default.
- W4311280444 cites W2154670681 @default.
- W4311280444 cites W2168691181 @default.
- W4311280444 cites W2212897984 @default.
- W4311280444 cites W2300160852 @default.
- W4311280444 cites W2304533799 @default.
- W4311280444 cites W2466915283 @default.
- W4311280444 cites W2552522590 @default.
- W4311280444 cites W2568182039 @default.
- W4311280444 cites W2586704604 @default.
- W4311280444 cites W2597025763 @default.
- W4311280444 cites W2624310346 @default.
- W4311280444 cites W2730519791 @default.
- W4311280444 cites W2748209653 @default.
- W4311280444 cites W2767072667 @default.
- W4311280444 cites W2768019189 @default.
- W4311280444 cites W2770828094 @default.
- W4311280444 cites W2784414491 @default.
- W4311280444 cites W2796923356 @default.
- W4311280444 cites W2800286167 @default.
- W4311280444 cites W2846588575 @default.
- W4311280444 cites W2885875860 @default.
- W4311280444 cites W2896424462 @default.
- W4311280444 cites W2905492903 @default.
- W4311280444 cites W2906959515 @default.
- W4311280444 cites W2917527600 @default.
- W4311280444 cites W2938245541 @default.
- W4311280444 cites W2947363523 @default.
- W4311280444 cites W2948856571 @default.
- W4311280444 cites W2951718918 @default.
- W4311280444 cites W2969100876 @default.
- W4311280444 cites W2978653889 @default.
- W4311280444 cites W2982198358 @default.
- W4311280444 cites W2983799945 @default.
- W4311280444 cites W2995220921 @default.
- W4311280444 cites W3006257197 @default.
- W4311280444 cites W3007475361 @default.
- W4311280444 cites W3024986856 @default.
- W4311280444 cites W3037915143 @default.
- W4311280444 cites W3047057449 @default.
- W4311280444 cites W3047494686 @default.
- W4311280444 cites W3088004394 @default.
- W4311280444 cites W3094439638 @default.
- W4311280444 cites W3101089668 @default.
- W4311280444 cites W3134566625 @default.
- W4311280444 cites W3167019654 @default.
- W4311280444 cites W3205385592 @default.
- W4311280444 cites W4200087860 @default.
- W4311280444 cites W4200504537 @default.
- W4311280444 cites W4226465983 @default.
- W4311280444 cites W4283168725 @default.
- W4311280444 cites W4284679271 @default.
- W4311280444 cites W4307460706 @default.
- W4311280444 cites W4307911825 @default.
- W4311280444 doi "https://doi.org/10.1158/2159-8290.cd-22-0968" @default.
- W4311280444 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36511802" @default.
- W4311280444 hasPublicationYear "2022" @default.
- W4311280444 type Work @default.
- W4311280444 citedByCount "5" @default.
- W4311280444 countsByYear W43112804442023 @default.